Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus-Reference-Cited by-同舟云学术

Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus

Published:2022 Issue: Volume:5 Page:100152
ISSN:2589-9090
Container-title:Journal of Translational Autoimmunity
language:en
Short-container-title:Journal of Translational Autoimmunity

Author:

Fanton Christie,Furie Richard,Chindalore Vishala,Levin Robert,Diab Isam,Dixit Neha,Haglund Cat,Gibbons Jacqueline,Hanan Nathan,Dickerson Daniel^ORCID,Zalevsky Jonathan,Kotzin Brian L.^ORCID

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference42 articles.

1. Systemic lupus erythematosus;Kaul;Nat. Rev. Dis. Prim.,2016

2. Unmet needs in the pathogenesis and treatment of systemic lupus erythematosus;Bakshi;Clin. Rev. Allergy Immunol.,2018

3. The pathogenesis of systemic lupus erythematosus – an update;Choi;Curr. Opin. Immunol.,2012

4. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus;von Spee-Mayer;Ann. Rheum. Dis.,2016

5. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases;Klatzmann;Nat. Rev. Immunol.,2015

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Future directions;Dubois' Lupus Erythematosus and Related Syndromes;2025

2. Cytokines in lupus;Dubois' Lupus Erythematosus and Related Syndromes;2025

3. Recent patents in allergy and immunology: The interleukin‐2 receptor pathway agonist rezpegaldesleukin (REZPEG) for the rescue of regulatory T cells in chronic inflammatory and autoimmune diseases;Allergy;2024-08-16

4. 729 - A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled, international, multicenter, study to evaluate the efficacy and safety of rezpegaldesleukin in adults with moderate-to-severe atopic dermatitis;British Journal of Dermatology;2024-08

5. 724 - A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin in adults with severe to very-severe alopecia areata;British Journal of Dermatology;2024-08